Bernstein received his B.S. in physics from Yale University, and his Ph.D. and M.D. from the University of Washington School of Medicine.
Career and research
Early career
Bernstein completed his residency in clinical pathology at Brigham and Women's Hospital, and his post-doctoral research in Stuart Schreiber’s lab at Harvard Chemistry. Together with Stuart Schreiber and Eric Lander (Broad Institute), Bernstein characterized the epigenetic landscape in pluripotent embryonic stem cells, leading to the first characterization of bivalent chromatin.[2]
Research in the Bernstein laboratory focuses on epigenetics and how changes in gene activity, as opposed to gene sequence, guide development and lead to disease. The lab uses high-throughput genomic technologies to study how chromatin controls gene activity in different contexts. Bernstein's major contributions include ChIP-seq technology, now the standard for mapping chromatin and protein-DNA interactions in mammalian cells,[3] the characterization of bivalent chromatin[2] that poises developmental genes for alternate fates in development, and the identification of epigenetic defects that cause brain tumors and treatment failures.[4][5][6][7] He also directs epigenome mapping centers for ENCODE and (formerly) the NIH Epigenomics project at the Broad Institute.
Recognition
Bernstein received an Early Career Scientist award from the Howard Hughes Medical Institute (2009), the Paul Marks prize for Cancer Research (2015),[8] and an NIH Pioneer award (2016).[9] He holds the Richard and Nancy Lubin Family Chair at the Dana–Farber Cancer Institute. Bernstein also serves on the editorial board of Science.